3SBio Inc.
HKSE: 1530.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jing Lou
- Employees
- 5,577
- Headquarters
- Shenyang, China
- IPO year
- 2015
- Market cap
- HK$55.8B
- Website
- https://www.3sbio.com
Loading 1530…
Loading profile data…Frequently asked questions about 1530
What does 3SBio Inc. (1530.HK) do?
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arth...
Where does 1530.HK trade?
3SBio Inc. (1530.HK) trades on the Hong Kong Stock Exchange.
What sector is 1530.HK in?
3SBio Inc. (1530.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 3SBio Inc.?
Jing Lou is the chief executive officer of 3SBio Inc. (1530.HK).
Where is 3SBio Inc. headquartered?
3SBio Inc. is headquartered in China.
Does 1530.HK pay a dividend?
Yes — 3SBio Inc. (1530.HK) paid a trailing twelve-month dividend of HKD 0.25 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 1530.HK go public?
3SBio Inc. (1530.HK) completed its initial public offering in 2015.